Honeywell International Inc. grew its position in shares of Celgene Corporation (NASDAQ:CELG) by 9.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 277,900 shares of the biopharmaceutical company’s stock after purchasing an additional 25,000 shares during the quarter. Celgene Corporation makes up about 1.4% of Honeywell International Inc.’s holdings, making the stock its 17th largest position. Honeywell International Inc.’s holdings in Celgene Corporation were worth $36,091,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Beach Investment Management LLC. boosted its stake in shares of Celgene Corporation by 1,935.3% during the second quarter. Beach Investment Management LLC. now owns 126,188 shares of the biopharmaceutical company’s stock worth $16,388,000 after buying an additional 119,988 shares during the period. Trust Investment Advisors boosted its stake in shares of Celgene Corporation by 10.7% during the second quarter. Trust Investment Advisors now owns 5,175 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 500 shares during the period. Novare Capital Management LLC boosted its stake in shares of Celgene Corporation by 0.6% during the second quarter. Novare Capital Management LLC now owns 48,519 shares of the biopharmaceutical company’s stock worth $6,301,000 after buying an additional 275 shares during the period. First Bank & Trust boosted its stake in shares of Celgene Corporation by 13.6% during the second quarter. First Bank & Trust now owns 3,384 shares of the biopharmaceutical company’s stock worth $440,000 after buying an additional 405 shares during the period. Finally, Retirement Systems of Alabama boosted its stake in shares of Celgene Corporation by 0.5% during the second quarter. Retirement Systems of Alabama now owns 544,286 shares of the biopharmaceutical company’s stock worth $70,686,000 after buying an additional 2,532 shares during the period. 79.36% of the stock is currently owned by institutional investors.

In related news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now owns 76,301 shares in the company, valued at approximately $10,264,010.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,233 shares of company stock valued at $6,268,259. 0.95% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/honeywell-international-inc-raises-holdings-in-celgene-corporation-celg.html.

Several equities research analysts have recently weighed in on CELG shares. Morgan Stanley downgraded shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research note on Thursday. Leerink Swann upgraded shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $94.42 to $150.00 in a research note on Friday, June 16th. They noted that the move was a valuation call. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research note on Monday, June 26th. Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a research note on Monday, August 28th. Finally, BTIG Research downgraded shares of Celgene Corporation from a “buy” rating to a “neutral” rating and increased their target price for the stock from $96.93 to $131.70 in a research note on Friday, June 30th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $150.60.

Shares of Celgene Corporation (CELG) opened at 140.01 on Friday. The stock has a market capitalization of $109.54 billion, a PE ratio of 43.36 and a beta of 1.88. The firm has a 50-day moving average of $138.98 and a 200 day moving average of $129.44. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.44 EPS. On average, equities analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.